Nephrol Dial Transplant (2002) 17: 1197-1203
© 2002 European Renal Association-European Dialysis and Transplant Association
Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy
1 Division of Nephrology, Department of Internal Medicine, 2 Section of Biostatistics and 3 Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN, USA
Background. Proteinuria (UP) >1.0 g/24 h at diagnosis is a well-known indicator of progressive renal disease in patients with IgA nephropathy (IgAN). To determine if persistent UP is a more sensitive marker for later progression of IgAN, the hypothesis was tested that the prior level and trend (slope) in UP for 1 year was better at predicting later end-stage renal disease (ESRD) (dialysis or transplant) than a current 24-h UP, serum creatinine (SC), SC slope, hypertension, or total glomerular histopathological score on index renal biopsy in an observational study of 154 high-risk patients enrolled in two clinical trials (IgAN 1, IgAN 2).
Methods. Measurements of 24-h UP and SC were made at time 0, 6 weeks, 6 months and 1 year in all patients, who were then followed for an additional 5.76 years and 1.63 years in the two studies, respectively. The Cox proportional hazards model was used to identify predictors of ESRD following the 1-year visit.
Results. Adjusting only for randomized treatment, nearly all UP variables (number of high readings, 1-year level, slopes), SC at 1 year, and SC trends (slopes) over the prior year were significantly associated with subsequent ESRD (all P values <0.05) in both studies. However, among the UP variables, the 1-year readings had the strongest association with ESRD in IgAN 1 (hazard ratio (HR), 95% CI, for a 1g increase: 1.5, 1.2,1.9), and the second strongest association (similar to UP trends) in IgAN 2 (1.4, 1.2,1.6). Males had lower rates of ESRD in both studies (IgAN 1 HR: 0.5, 0.2,1.2, P=0.11; IgAN 2 HR: 0.2, 0.1,0.6, P=0.002). In the multivariate analyses that examined all clinical and histological variables, 1-year levels of 24-h UP and SC, and female gender were independently associated with subsequent ESRD.
Conclusion. In a high-risk patient with IgAN, the current 24-h UP and SC measurements are as good predictors of subsequent ESRD as UP and SC trends and levels over the prior year. Additionally, it appears that females have poorer outcomes than males.
Keywords: IgA nephropathy; prognosis; proteinuria
Correspondence and offprint requests to: James V. Donadio MD, Emeritus Staff, Mayo Clinic, 200 First Street South West, Stabile 722, Rochester, MN 55905–0001, USA. Email: donadio.james{at}mayo.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. N. Reich, S. Troyanov, J. W. Scholey, D. C. Cattran, and for the Toronto Glomerulonephritis Registry Remission of Proteinuria Improves Prognosis in IgA Nephropathy J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3177 - 3183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Cattran Is Proteinuria Reduction by Angiotensin-Converting Enzyme Inhibition Enough to Prove Its Role in Renal Protection in IgA Nephropathy? J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1633 - 1634. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hogg, L. Fitzgibbons, C. Atkins, N. Nardelli, R. C. Bay, and for the North American IgA Nephropathy Study Group Efficacy of Omega-3 Fatty Acids in Children and Adults with IgA Nephropathy Is Dosage- and Size-Dependent Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1167 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xia, Y. Li, Y. Du, N. Yang, C. Li, J. C. K. Leung, M. F. Lam, W. Huang, S. Chen, P. H. Maxwell, et al. Association of MEGSIN 2093C-2180T haplotype at the 3' untranslated region with disease severity and progression of IgA nephropathy Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1570 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Appel To Treat or Not to Treat IgA Nephropathy? That Is the Question! Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 347 - 348. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hogg, J. Lee, N. Nardelli, B. A. Julian, D. Cattran, B. Waldo, R. Wyatt, J. C. Jennette, R. Sibley, K. Hyland, et al. Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Barratt and J. Feehally IgA Nephropathy J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2088 - 2097. [Full Text] [PDF]
|
|
|
|
|
|
M. Laville and E. Alamartine Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy Nephrol. Dial. Transplant., August 1, 2004; 19(8): 1947 - 1951. [Full Text] [PDF]
|
|